April 24, 2017
A New Jersey federal judge on Monday permanently blocked Amerigen Pharmaceuticals Inc. from moving forward with a generic version of Shire LLC's attention deficit hyperactivity disorder medication Adderall XR before the patents expire, pursuant to a settlement between the drugmakers.
July 27, 2015
Amerigen Pharmaceuticals Inc. has to let Shire LLC look through its confidential information, namely its abbreviated new drug application, to figure out if it infringed Shire's patent for Adderall XR, a New Jersey magistrate judge ruled Friday.